
Tirzepatide, nerve stimulation, and oral AD109 are reshaping OSA care as phenotyping replaces the one-size-fits-all CPAP default.

Ashesha Mechineni, MD, is a clinical assistant professor at University of Illinois Chicago.

Tirzepatide, nerve stimulation, and oral AD109 are reshaping OSA care as phenotyping replaces the one-size-fits-all CPAP default.